top of page
mDETECT

Transforming Cancer Care Through Ultra-Sensitive Liquid Biopsy 

Harnessing target-specific DNA methylation to deliver rapid, accurate, and accessible diagnostic tools for early detection, monitoring, and minimal residual disease (MRD).

Why mDETECT?

  • Ultra-Sensitive Detection where we can identify circulating tumor DNA (ctDNA) down to 0.01% LOD.

  • Multi-Cancer Test with applications spanning Breast, Ovarian, Lung, Prostate and more.

  • Seamless Integration across any platform and designed for rapid, automated NGS workflows to deliver analysis in minutes.

MDetect Edited Pictures-13.jpg

Our Impact

At mDETECT, we are committed to transforming how cancer patients are managed. Using our innovative and advanced technology, oncologists receive detailed and personalized data on cancer progression, relapse, and treatment response for each patient.

Contact us

We are actively collaborating with clinical networks, diagnostic partners, and industry leaders to bring accessible precision monitoring to market.

Get in Touch:

mdetect
bottom of page